Abstract:Objective To investigate the effect of ulinastatin treatment on the inflammatory factor expression and prognosis in patients with ventilator-associated pneumonia (VAP). Methods One hundred patients with VAP were enrolled, and the patients were given the standardized treatment of VAP. The patents were divided into high dose group (33 cases, using the ulinastatin 20 000 U/d), normal dose group (34 cases, using the ulinastatin 10 000 U/d) and control group (33 cases, no using the ulinastatin) by random digits table method. The serum C-reactive protein (CRP), procalcitonin, interleukin (IL)-6 and tumor necrosis factor (TNF)-αlevels at the first, third, fifth and seventh day of diagnosis were detected. All the patients were followed up for 1 month, and the antibiotics treatment time, mechanical ventilation time, ICU stay time and mortality were recorded. Results The CRP, procalcitonin, TNF-αand IL-6 from the first day of diagnosis to the seventh day of diagnosis in 3 groups showed the downward trend, and there were statistical differences (P<0.05). There were no statistical differences in CRP and procalcitonin at the third, fifth and seventh day of diagnosis among 3 groups (P>0.05). At the third, fifth and seventh day of diagnosis, the TNF-α levels in high dose group were (46.02 ± 4.65), (23.88 ± 7.76) and (11.05 ± 2.56) ng/L, the IL-6 levels were (15.53 ± 4.54), (11.33 ± 3.45) and (6.62 ± 2.45) ng/L;the TNF-αlevels in normal dose group were (56.02 ± 6.42), (38.88 ± 9.34) and (27.05 ± 3.42) ng/L, the IL-6 levels were (18.23 ± 2.45), (15.33 ± 4.34) and (11.23 ± 3.34) ng/L; the TNF-α levels in control group were (68.13 ± 4.77), (52.88 ± 7.46) and (42.12 ± 3.76) ng/L, the IL-6 levels were (20.02 ± 3.23), (17.23 ± 2.34) and (15.33 ± 2.33) ng/L. The TNF-αand IL-6 levels at the third, fifth and seventh day of diagnosis in high dose group were significantly lower than those in normal dose group and control group, and those in the normal dose group were significantly lower than those in control group, and there were statistical differences (P<0.05). The mechanical ventilation time, antibiotics treatment time and ICU stay time in high dose group were significantly shorter than those in normal group and control group:(15.34 ± 5.67) d vs. (18.44 ± 6.32) and (22.34 ± 5.21) d, (7.45 ± 2.54) d vs. (10.45 ± 4.56) and (14.43 ± 6.24) d, (18.42 ± 7.45) d vs. (20.43 ± 4.98) and (26.35 ± 5.97) d, and those in normal group were significantly shorter than those in control group, and there were statistical differences (P<0.05). There was no statistical differences in the mortality among 3 groups (P>0.05). Conclusions Ulinastatin can inhibit the expression of IL-6 and TNF-α in patents with VAP, shorten the antibiotics treatment time, mechanical ventilation time, ICU stay time and mortality, and improve prognosis.

The Application of Tigecycline in the Treatment of Severe Ventilator-associated Pneumonia and its Influence on Respiratory Mechanics and Serum Inflammatory Factors

Observation of Tigecycline Administration in Gram-Negative Bacteria Infected Children with Ventilator-Associated Pneumonia

Salvage Tigecycline in High Risk Febrile Neutropenic Patients with Hematological Malignancies: a Prospective Multicenter Study.

Investigation of the Clinical Studies of Traditional Chinese Medicine and Western Medicine in the Treatment of Disorders Related to Ventilators

High-dose Tigecycline for the Treatment of Nosocomial Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections A Retrospective Cohort Study

The application of reduced glutathione in the treaatment of severe pneumonia

Efficacy and Impact on Serum Matrix Metalloproteinase-9 of Long-Term Non-Invasive Positive Pressure Ventilation Combined with Inhaling Corticosteroids in Patients with Stable Severe Chronic Obstructive Pulmonary Disease Complicated with Respiratory Failure

Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units

Clinical efficacy of tigecycline combination therapy in treatment of multidrug-resistant bacteria infections in NICU patients

Efficacy of tigecycline in pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia

Preliminary Experience of Tigecycline Treatment in Critically Ill Children with Ventilator-Associated Pneumonia

Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring

Efficacy and Safety of Tigecycline Monotherapy Vs. Imipenem/cilastatin in Chinese Patients with Complicated Intra-Abdominal Infections: a Randomized Controlled Trial

Immunomodulatory effect of tigecycline on lipopolysaccharide-induced sepsis

Effect of Ulinastatin Treatment on the Inflammatory Factor Expression and Prognosis in Patients with Ventilator-Associated Pneumonia

A Multicenter, Double-Blind, Randomized, Comparison Study of the Efficacy and Safety of Tigecycline to Imipenem/cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects in China

Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation

Influence of continuous renal replacement therapy on the plasma concentration of tigecycline in patients with septic shock: A prospective observational study

Retrospective analysis of tigecycline shows that it may be an option for children with severe infections

Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections